The 4 stages every biotech operates in (and the ERP has to support)
A biotech company is rarely a single company over time. Pre-revenue research operations have different finance and supply chain needs from clinical-stage trial sponsors, which differ from BLA-stage pre-launch organizations, which differ again from commercial operations.
Clinical-stage biotech companies carry one of the most complex finance profiles in existence: CRO accruals calculated outside the ERP, milestone revenue that lives in spreadsheets, and pre-IPO audit readiness built on goodwill. The challenge is not just supporting one stage. It is supporting all of them on the same platform without rebuilding.
Oracle NetSuite's Life Sciences ERP is designed for the lifecycle. The configuration work is mapping each stage's specific requirements to the platform's capabilities and configuring the transitions as configuration changes, not projects.
The IND to BLA transition is not a project. It is a configuration. If the ERP has to be rebuilt at every stage, it was not built for biotech in the first place.
Stage 01: Pre-IND and IND-enabling work
Operational reality
The company is doing preclinical research, manufacturing process development, and IND-enabling toxicology studies. Spending is high. Revenue is grant funding, collaboration income, or none. Headcount is small but specialized.
What the ERP needs to support
- Project-based R and D spending with cost per program visibility
- Grant tracking with fund accounting for federal, foundation, or NIH funding
- Collaboration revenue recognition under ASC 606 for license payments and milestone fees
- CRO and CMO accruals on a defined cadence
- Stock-based compensation accounting under ASC 718
- Audit-ready records for any future IPO due diligence
Configuration approach
Every dollar of spend codes to a program (target, candidate, indication) and a phase (discovery, preclinical, IND-enabling). Contract Lifecycle Management tracks collaboration agreements with milestone and royalty obligations. Vendor Onboarding and Approved Supplier List manage the CRO and CMO relationships. Grant accounting uses class or fund dimensions for the program-level visibility funders require.
Stage 02: Clinical-stage (Phase I through Phase III)
Operational reality
The company is running clinical trials. CRO spend is the largest line item. CMO manufacturing is happening for clinical supply. Milestones are triggering at investigators, regulators, and partners. The pipeline expands or contracts based on data readouts.
What the ERP needs to support
- CRO accrual model that matches contract terms (FTE-based, deliverable-based, or hybrid)
- Clinical supply manufacturing with lot tracking and chain of custody to trial sites
- Investigator grant tracking with site-specific payment terms and milestone triggers
- Milestone revenue recognition under ASC 606 for partnership agreements
- R and D expense recognition under ASC 730 with clear program-level visibility
- Multi-currency for global trial operations
Configuration approach
Project structure deepens. Each clinical study is a subproject under the program. Each site is a sub-subproject under the study. CRO purchase orders carry deliverable-based or FTE-based accrual schedules. Clinical supply lots are tracked through 3PL Integration with chain of custody to trial sites. Milestone revenue recognition runs against Contract Lifecycle Management records.
Stage 03: BLA-stage (filing through approval)
Operational reality
The clinical program is positive. The company is preparing the BLA submission, scaling manufacturing for commercial supply, building commercial infrastructure (medical affairs, market access, sales), and beginning pre-launch inventory production. Cost base is high and growing. Investor scrutiny is intense.
What the ERP needs to support
- Pre-launch inventory capitalization under defined criteria with audit-ready support
- Manufacturing scale-up cost tracking with capacity utilization analysis
- Commercial infrastructure spending with cost per launch visibility
- Continued clinical operations for post-marketing commitments
- Pre-revenue commercial readiness with full GAAP COGS configuration prepared but not yet active
The capitalization decision
The transition from R and D expense to pre-launch inventory capitalization is the single most material accounting decision at this stage. Per ASC 330, inventory is capitalized when the future economic benefit is reasonably assured. The point of reasonable assurance varies by company and product:
- Some companies begin capitalizing at PDUFA action plus 60 days, when approval is highly probable and labor for commercial production is ramping
- Some begin at Phase III topline data, when the data supports a clear path to approval
- Some wait until BLA acceptance, when FDA has accepted the submission for review
- The most conservative approach is at approval, after the FDA action letter
The decision is a policy choice. The ERP configuration has to support whatever policy the audit committee adopts. Archer's biotech configuration includes the item record settings, accounting policy logic, and item categorization that drive the right behavior for the elected policy.
Stage 04: Commercial launch and beyond
Operational reality
Product is approved. Commercial inventory is on the shelf or being shipped. Revenue is recognizing. Gross-to-net deductions are flowing through. Post-marketing commitments are running. The company is now a commercial pharma.
What the ERP needs to support
- Full COGS treatment for commercial product
- Gross-to-net waterfall with all deduction categories (commercial rebates, Medicaid, 340B, copay assistance, returns)
- DSCSA serialization and trading partner integration
- Sales operations: territory management, contract administration, distribution channel reporting
- Sunshine Act reporting through Sunshine Act Reporting module
- Continued clinical operations for post-marketing commitments and label expansion studies
Configuration approach
The commercial-stage configuration overlays clinical-stage operations. Clinical work continues; commercial work begins. NetSuite supports both modes simultaneously. The configuration changes are activations, not replacements.
Stage transition configuration: what actually has to change
The transition from one stage to another is a configuration change, not a project. The specific changes:
| Transition | What changes in NetSuite |
|---|---|
| Pre-IND to clinical | Clinical supply item records created. CRO PO accrual workflow activated. Multi-currency enabled. |
| Clinical to BLA-stage | Pre-launch inventory item records created. Commercial chart of accounts prepared. Manufacturing scale-up project initiated. |
| BLA-stage to commercial launch | Capitalization policy activates per accounting policy. COGS calculation enabled. Gross-to-net waterfall activated. DSCSA serialization activated. |
None of these are platform rebuilds. They are configuration changes that take days or weeks, not months.
What investors and auditors actually see
A biotech that runs through all 4 stages on the same platform produces consistent reporting. The investor sees the same cost per program report from preclinical through commercial. The auditor sees an unbroken audit trail from grant funding through commercial revenue. The CFO has continuity in the financial system through the most important transitions in the company's history.
A biotech that rebuilds at every transition loses that continuity. The investor presentation requires reconstruction. The auditor asks for bridge schedules between old and new systems. The CFO spends launch quarter validating data instead of running the launch.
Related on archerinsights.com
- Biotech and pharmaceuticals industry page. Archer's configuration for clinical and commercial biotech operations.
- NetSuite for biologics hub. Foundation configuration for biologics from IND through commercial.
- Cell and gene therapy industry page. Advanced therapy stage transitions.
- CRO industry page. Sponsor-side CRO management.
- Contract Lifecycle Management. Collaboration agreement and milestone tracking.
- Quality Management System. GMP and Part 11 compliance through every stage.